Our Story

Forward-looking statements
This presentation contains "forward-looking statements." These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements may include, without
limitation, statements about optimizing shareholder return, expected revenue breakdown; and statements about the transaction pursuant to which Mylan N.V. (“Mylan”) combined with Pfizer Inc.’s Upjohn business (the “Upjohn
Business”) in a Reverse Morris Trust transaction (the “Combination”) to form Viatris Inc. (“Viatris™” or the “Company”) effective as of the closing of the Combination, the benefits and synergies of the Combination, future opportunities for
the Company and products and any other statements regarding the Company’s future operations, financial or operating results, capital allocation, dividend policy, debt ratio, anticipated business levels, future earnings, planned activities,
anticipated growth, market opportunities, strategies, competitions, and other expectations and targets for future periods. Forward-looking statements may often be identified by the use of words such as “will”, “may”, “could”, “should”,
“would”, “project”, “believe”, “anticipate”, “expect”, “plan”, “estimate”, “forecast”, “potential”, “pipeline”, “intend”, “continue”, “target”, “seek” and variations of these words or comparable words. Because forward-looking statements
inherently involve risks and uncertainties, actual future results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not
limited to: the potential impact of public health outbreaks, epidemics and pandemics, including the ongoing challenges and uncertainties posed by the COVID-19 pandemic; the Company’s failure to achieve expected or targeted future
financial and operating performance and results; the integration of Mylan and the Upjohn Business being more difficult, time consuming or costly than expected; the possibility that the Company may be unable to achieve expected
benefits, synergies and operating efficiencies in connection with the Combination within the expected timeframe or at all or to successfully integrate Mylan and the Upjohn Business; the possibility that the Company may be unable to
achieve expected benefits, synergies and operating efficiencies in connection with business transformation initiatives, strategic acquisitions, strategic initiatives or restructuring programs within the expected timeframes or at all; the ability
to meet expectations regarding the accounting and tax treatments of the Combination or other acquisitions; actions and decisions of healthcare and pharmaceutical regulators; changes in relevant laws and regulations, including but not
limited to changes in the U.S. tax code and healthcare and pharmaceutical laws and regulations in the U.S. and abroad; the ability to attract and retain key personnel, including that the retention of key employees may be more difficult
following the Combination; the Company’s liquidity, capital resources and ability to obtain financing; any regulatory, legal or other impediments to the Company’s ability to bring new products to market, including but not limited to where
the Company uses its business judgment and decides to manufacture, market and/or sell products, directly or through third parties, notwithstanding the fact that allegations of patent infringement(s) have not been finally resolved by the
courts (i.e., an “at-risk launch”); success of clinical trials and the Company’s or its partners’ ability to execute on new product opportunities and develop, manufacture and commercialize products; any changes in or difficulties with the
Company’s manufacturing facilities, including with respect to inspections, remediation and restructuring activities, supply chain or inventory or the ability to meet anticipated demand; the scope, timing and outcome of any ongoing legal
proceedings, including government investigations, and the impact of any such proceedings on the Company’s financial condition, results of operations and/or cash flows; identifying, acquiring, and integrating complementary or strategic
acquisitions of other companies, products, or assets being more difficult, time-consuming or costly than anticipated; any significant breach of data security or data privacy or disruptions to our information technology systems; risks
associated with international operations, including our operations in China; the ability to protect intellectual property and preserve intellectual property rights; changes in third-party relationships; the effect of any changes in the
Company’s or its partners’ customer and supplier relationships and customer purchasing patterns, including customer loss and business disruption being greater than expected following the Combination; the impacts of competition,
including decreases in sales or revenues as a result of the loss of market exclusivity for certain products; changes in the economic and financial conditions of the Company or its partners; uncertainties regarding future demand, pricing
and reimbursement for the Company’s products; uncertainties and matters beyond the control of management, including but not limited to general political and economic conditions and global exchange rates; and inherent uncertainties
involved in the estimates and judgments used in the preparation of financial statements, and the providing of estimates of financial measures, in accordance with accounting principles generally accepted in the United States of America
(“U.S. GAAP”) and related standards or on an adjusted basis. For more detailed information on the risks and uncertainties associated with Viatris, the final information statement, dated August 6, 2020, which is attached as Exhibit 99.1
to Upjohn’s Current Report on Form 8-K filed on August 6, 2020. You can access these filings with the SEC through the SEC website at www.sec.gov or through the Company’s website and the Company strongly encourages you to do
so. Viatris routinely posts information that may be important to investors on our website at investor.viatris.com, and we use this website address as a means of disclosing material information to the public in a broad, non-exclusionary
manner for purposes of the SEC’s Regulation Fair Disclosure (Reg FD). The contents of our website are not incorporated into this release. Viatris undertakes no obligation to update any statements herein for revisions or changes after
the date of this release other than as required by law.

This document contains proprietary information of Viatris Inc. Unauthorized use, duplication, dissemination or disclosure to third parties is strictly prohibited.
© 2020 Viatris Inc. All Rights Reserved. VIATRIS and the Viatris Logo are trademarks of Mylan Inc., a Viatris company. 2
A New Kind of Healthcare
Company
A new business model with enhanced global scale and an
operating platform with expanded commercial capabilities

A strong financial profile

A dedication to Total Shareholder Return

A Unique Global Healthcare Gateway™ to fuel growth and address

unmet needs

A commitment to Corporate Social Responsibility

This document contains proprietary information of Viatris Inc. Unauthorized use, duplication, dissemination or disclosure to third parties is strictly prohibited.
© 2020 Viatris Inc. All Rights Reserved. VIATRIS and the Viatris Logo are trademarks of Mylan Inc., a Viatris company.
3
 In a world that is perpetually changing, there is an increasing
need for steady leadership – companies demonstrating the
courage to face the emerging healthcare challenges with passion
and compassion. We are uniquely positioned to be a source of
stability with the commitment, capability, and vision to
meet the world’s evolving patient needs.
Our Mission:
At Viatris, we see healthcare not as it is but
as it should be. We act courageously and are
uniquely positioned to be a source of stability
in a world of evolving healthcare needs.
Viatris empowers people worldwide
to live healthier at every stage of life.
We do so via:

Access Leadership Partnership

Providing high quality Advancing sustainable Leveraging our collective
trusted medicines operations and expertise to connect people
regardless of geography innovative solutions to to products and services
or circumstance improve patient health

This document contains proprietary information of Viatris Inc. Unauthorized use, duplication, dissemination or disclosure to third parties is strictly prohibited.
© 2020 Viatris Inc. All Rights Reserved. VIATRIS and the Viatris Logo are trademarks of Mylan Inc., a Viatris company. 6
 Experienced Leadership to Optimize Total Shareholder
Return and Broaden Access to Medicine

STRATEGIC OVERSIGHT OVERALL PERFORMANCE AND BUSINESS AND FINANCIAL PERFORMANCE

AND LEADERSHIP STRATEGY DEVELOPMENT OPERATIONAL EXECUTION AND DISCIPLINE

Robert J. Coury Michael Goettler Rajiv Malik Sanjeev Narula

Executive Chairman Chief Executive Officer President Chief Financial Officer

This document contains proprietary information of Viatris Inc. Unauthorized use, duplication, dissemination or disclosure to third parties is strictly prohibited.
© 2020 Viatris Inc. All Rights Reserved. VIATRIS and the Viatris Logo are trademarks of Mylan Inc., a Viatris company. 7
Sustainable, Diverse and
Differentiated Portfolio
Our global portfolio includes medicines across a broad range of major therapeutic
areas, spanning both noncommunicable and infectious diseases.

OVER-THE-COUNTER EXPECTED COMBINED REVENUE

BRANDS BIOSIMILARS
(OTC) BREAKDOWN

Best-in-class, iconic One of the industry’s Variety of OTCs, OTC 6%

brand-name products largest and most including dietary BIOLOGICS
diverse global supplements,
4%
and global key brands
biosimilars franchises homeopathics
and cosmetics
Areas of Focus: US
- Oncology GENERIC
15%
- Immunology
ACTIVE
GENERICS
- Endocrinology PHARMACEUTICAL BRAND
- Ophthalmology INGREDIENTS (API) EX-US
56%

- Dermatology GENERIC
A diverse range of One of the world’s 19%

generic medicines, largest producers

including branded of API
and complex generics

This document contains proprietary information of Viatris Inc. Unauthorized use, duplication, dissemination or disclosure to third parties is strictly prohibited.
© 2020 Viatris Inc. All Rights Reserved. VIATRIS and the Viatris Logo are trademarks of Mylan Inc., a Viatris company. 8
Unparalleled Global Reach
Our strong global commercial infrastructure is comprised of four business
segments that enable us to serve patients through retail and pharmacy
establishments, wholesalers, governments, institutions, physicians and
other customers in more than 165 countries and territories.

Developed Emerging Markets Greater China Japan, Australia

Markets & New Zealand
(JANZ)

This document contains proprietary information of Viatris Inc. Unauthorized use, duplication, dissemination or disclosure to third parties is strictly prohibited.
© 2020 Viatris Inc. All Rights Reserved. VIATRIS and the Viatris Logo are trademarks of Mylan Inc., a Viatris company. 9
Delivered Through
a Unique Global Platform
We leverage our manufacturing, scientific and medical
capabilities around the world to advance innovative
solutions for patients.

Truly Global
Supply Network

~50 35,000+ 2,500+ 1,000+

with local proximity

Manufacturing Marketing Scientists1 Regulatory

Sites1 Authorizations1 Experts1
Strong Technical
Resources
Research & Development,
Quality, Medical, 80B+ 135+ 600+
Pharmacovigilance Annual Dose Annual Health Medical & Product
and Regulatory capabilities Capacity1 Authority Safety Professionals1
across the globe Inspections1

1. Data as of November 2020.

This document contains proprietary information of Viatris Inc. Unauthorized use, duplication, dissemination or disclosure to third parties is strictly prohibited.
© 2020 Viatris Inc. All Rights Reserved. VIATRIS and the Viatris Logo are trademarks of Mylan Inc., a Viatris company.
Our Commitment to Quality
Protecting patients and consumer health by ensuring
the quality and safety of our products is at the heart
of how we operate across our network. From product
development to making or sourcing raw materials to
producing finished dosage forms, every step of our
development, manufacturing and monitoring
processes is grounded in this commitment.

This document contains proprietary information of Viatris Inc. Unauthorized use, duplication, dissemination or disclosure to third parties is strictly prohibited.
© 2020 Viatris Inc. All Rights Reserved. VIATRIS and the Viatris Logo are trademarks of Mylan Inc., a Viatris company. 11
 Our Global Healthcare Gateway
Creating better value for all stakeholders
Broad Global Commercial while addressing unmet needs. Patient
Reach Across Channels
Access
& Therapeutic Areas

Global Supply
Resilient
& Manufacturing
Supply Chain
Network

Expansive Technical,
Science & Regulatory, Innovative Health
Legal & Compliance Solutions
Expertise

Cost-Efficient Sustainable
Operating Platform Access

Disciplined Capital
Future of Care
Investment Governance
As the world’s healthcare needs evolve, our unique Global Healthcare Gateway®
offers partners ready access to more markets and patients worldwide through our
unmatched global infrastructure and expertise, making Viatris a true Partner of Choice®.

This document contains proprietary information of Viatris Inc. Unauthorized use, duplication, dissemination or disclosure to third parties is strictly prohibited.
© 2020 Viatris Inc. All Rights Reserved. VIATRIS and the Viatris Logo are trademarks of Mylan Inc., a Viatris company. 12
 Committed to Corporate
Social Responsibility
We work to advance responsible and sustainable
operations, recognizing that all our actions affect
our stakeholders and the communities we serve.

Patient Employee
Health Health

Global Community
Public Health Health

Environmental
Health

This document contains proprietary information of Viatris Inc. Unauthorized use, duplication, dissemination or disclosure to third parties is strictly prohibited.
© 2020 Viatris Inc. All Rights Reserved. VIATRIS and the Viatris Logo are trademarks of Mylan Inc., a Viatris company. 13
Our People
We do it all with a collective spirit of
resiliency, driving steadfastly forward
until each challenge is addressed and
every opportunity embraced. We are
inspired by this moment of shared
purpose and confidence – because as
Viatris, our workforce of ~45,000 knows
our company is more than a place to
work. Viatris is a place where you can
learn and grow with an exciting new
company and make a difference in
the world.

This document contains proprietary information of Viatris Inc. Unauthorized use, duplication, dissemination or disclosure to third parties is strictly prohibited.
© 2020 Viatris Inc. All Rights Reserved. VIATRIS and the Viatris Logo are trademarks of Mylan Inc., a Viatris company. 14
As a Campus Intern at Viatris India, you can expect

To Work alongside Supportive A chance to work Frequent Check- Ins

Industry Experts in Mentors from on projects to support learning
the Pharmaceutical specific stream/ which make a followed by the
space function Business Impact Final Review

Structured Start to 6-8 Weeks of Real - Time

End Internship relevant function Learning
Experience exposure Opportunities

This document contains proprietary information of Viatris Inc. Unauthorized use, duplication, dissemination or disclosure to third parties is strictly prohibited.
© 2020 Viatris Inc. All Rights Reserved. VIATRIS and the Viatris Logo are trademarks of Mylan Inc., a Viatris company. 15
 Stay Connected
Follow us on these channels to stay up-to-date on the latest Viatris news.

Viatris.com Linkedin Twitter YouTube

Follow Viatris on LinkedIn Follow us @viatrisinc Subscribe to our
YouTube channel

This document contains proprietary information of Viatris Inc. Unauthorized use, duplication, dissemination or disclosure to third parties is strictly prohibited.
© 2020 Viatris Inc. All Rights Reserved. VIATRIS and the Viatris Logo are trademarks of Mylan Inc., a Viatris company. 16